HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Washington, C. Articles by Berner, B. Search for Related Content PubMed PubMed Citation Articles by Washington, C. Articles by Berner, B.

CARLA WASHINGTON, PH.D., is Manager, Clinical Pharmacokinetics, and EDDIE HOU, PH.D., is Senior Director, Formulations and Pharmacokinetics, Depomed, Inc., Menlo Park, CA. NICKI HUGHES, PH.D., is Director, Bioanalytical Laboratory, Biovail Contract Research, Toronto, Ontario, Canada. BRET BERNER, PH.D., is Vice President, Product Development, Depomed, Inc.

Address correspondence to Dr. Berner at Depomed, Inc., 1360 O’Brien Drive, Menlo Park, CA 94025-1436 (bberner{at}depomedinc.com).

Purpose. The effect of omeprazole on the oral bioavailability and urinary exposure of the Depomed formulation of extended-release (ER) ciprofloxacin was studied. Methods. A two-way crossover study was conducted in healthy subjects. Subjects received either a single dose of ER ciprofloxacin 1000 mg or a single dose of ER ciprofloxacin 1000 mg following three days of treatment with omeprazole 40 mg. Blood and urine samples were collected over 36 hours, and ciprofloxacin concentrations were determined using high-performance liquid chromatography. Results. Twenty-seven subjects (16 men, 11 women) received both treatments. The mean maximum concentration, mean area under the plasma-versus-concentration curve, and mean amount of ciprofloxacin excreted in urine were similar between the two treatments and met strict bioequivalence criteria. Conclusion. Omeprazole did not affect the plasma or urinary pharmacokinetics of an oral ER formulation of ciprofloxacin. Index terms: Blood levels; Ciprofloxacin hydrochloride; Drug interactions; Drugs, availability; Excretion; Gastrointestinal drugs; Omeprazole; Pharmacokinetics; Quinolones; Sustained-action medications; Urine levels

 

This article has been cited by other articles:

				C. Washington, S. Y. E. Hou, N. C. Hughes, C. Campanella, and B. Berner Ciprofloxacin Prolonged-Release Tablets Do Not Affect Warfarin Pharmacokinetics and Pharmacodynamics J. Clin. Pharmacol., October 1, 2007; 47(10): 1320 - 1326. [Abstract] [Full Text] [PDF]